CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

EnoxaparinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug544 New screening strategy Wiki 1.00
drug780 Standard screening strategy Wiki 1.00

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.12
D011014 Pneumonia NIH 0.08
D007239 Infection NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.15

There is one clinical trial.

Clinical Trials

1 Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial

The purpose of this study is to determine whether a higher dose of low molecular weight heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin 40 mg o.d.) in reducing thromboembolic events in COVID-19 patients.

NCT04366960 Covid19 Drug: Enoxaparin

Primary Outcomes

Description: Deep vein thrombosis events diagnosed by serial compression ultrasonography and pulmonary embolism events diagnosed by computed tomography scan

Measure: Incidence of venous thromboembolism detected by imaging

Time: 30 days

Secondary Outcomes

Description: death, venous thromboembolism, use of mechanical ventilation, stroke, acute myocardial infarction and admission to an intensive care

Measure: In hospital major complications

Time: 30 days

Description: Deep venous thrombosis events diagnosed by serial compression ultrasonography

Measure: Number of deep venous thrombosis events

Time: 30 days

Description: Maximum sequential organ failure assessment (SOFA) score comparison between the two groups. The SOFA score ranges from 0 to 24. Higher SOFA score is associated with a greater risk of death or prolonged intensive care unit stay.

Measure: Sequential organ failure assessment

Time: 30 days

Description: To compare C-reactive protein levels as % above the upper reference limit [URL]) among the two groups.

Measure: C-reactive protein

Time: 30 days

Description: To compare Interleukin‐6 levels as % above the upper reference limit [URL]) among the two groups.

Measure: Interleukin‐6

Time: 30 days

Description: To D-dimer compare levels as % above the upper reference limit [URL]) among the two groups.

Measure: D-dimer

Time: 30 days

Description: To compare hs-troponin levels as % above the upper reference limit [URL]) among the two groups.

Measure: hs-troponin levels

Time: 30 days

Description: To compare the incidence of SARS-CoV-2-related Acute Respiratory Distress Syndrome (ARDS) between the two groups.

Measure: Acute Respiratory Distress Syndrome

Time: 30 days

Description: To compare length of hospital stay between the two groups.

Measure: Hospital stay

Time: 30 days

Description: To compare measures of right ventricular function at trans-thoracic echocardiography or CT between admission and follow-up, whenever available

Measure: Right ventricular function

Time: 30 days

Description: Pulmonary embolism events diagnosed by computed tomography scan

Measure: Number of pulmonary embolism events

Time: 30 days

No related HPO nodes (Using clinical trials)